Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 04 2022
21 04 2022
Historique:
received:
17
06
2021
accepted:
06
04
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Large-scale target cell isolation from patient blood preparations is one of the critical operations during drug product manufacturing for personalized cell therapy in immuno-oncology. Use of high-affinity murine antibody coated magnetic nanoparticles that remain on isolated cells is the current standard applied for this purpose. Here, we present the transformation of previously described technology - non-magnetic immunoaffinity column chromatography-based cell selection with reversible reagents into a new clinical-grade cell isolation platform called Automated Traceless Cell affinity chromatography (ATC). ATC is a fully closed and GMP-compliant cell selection and manufacturing system. Reversibility of reagents enables (sequential) positive cell selection, optionally in combination with depletion columns, enabling capture of highly specific cell subsets. Moreover, synergy with other Streptamer-based technologies allows novel uses beyond cell isolation including integrated and automated on-column target cell activation. In conclusion, ATC technology is an innovative as well as versatile platform to select, stimulate and modify cells for clinical manufacturing and downstream therapies.
Identifiants
pubmed: 35449227
doi: 10.1038/s41598-022-10320-x
pii: 10.1038/s41598-022-10320-x
pmc: PMC9023455
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6572Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Transfus Med Hemother. 2019 Feb;46(1):47-54
pubmed: 31244581
Nat Biomed Eng. 2019 Dec;3(12):974-984
pubmed: 31182835
Annu Rev Immunol. 2019 Apr 26;37:145-171
pubmed: 30526160
SLAS Technol. 2018 Aug;23(4):326-337
pubmed: 29281498
Sci Rep. 2018 Nov 13;8(1):16731
pubmed: 30425259
Biomedicines. 2017 Jun 21;5(2):
pubmed: 28635677
Lancet Oncol. 2020 Mar;21(3):e168-e178
pubmed: 32135120
J Clin Invest. 2016 Nov 1;126(11):4262-4272
pubmed: 27760047
Nat Biomed Eng. 2019 Oct;3(10):783-795
pubmed: 31209354
Methods Mol Biol. 2015;1295:33-42
pubmed: 25820711
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Cytometry A. 2010 Jul;77(7):643-7
pubmed: 20583279
Cytotherapy. 2018 Mar;20(3):394-406
pubmed: 29287970
Eur J Biochem. 1995 Aug 1;231(3):823-30
pubmed: 7649183
Nat Rev Cancer. 2012 Oct;12(10):671-84
pubmed: 22996603
J Immunol. 1987 Sep 1;139(5):1589-96
pubmed: 2442250
Biotechnology (N Y). 1995 Feb;13(2):155-60
pubmed: 9634756
Lab Chip. 2020 Jun 30;20(13):2263-2273
pubmed: 32459276
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499101
Protein Eng. 1993 Jan;6(1):109-22
pubmed: 8433964
Nat Protoc. 2007;2(6):1528-35
pubmed: 17571060
Bioconjug Chem. 2011 Mar 16;22(3):362-8
pubmed: 21314110
PLoS One. 2012;7(4):e35798
pubmed: 22545138
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4591-4596
pubmed: 28408395
Cytotherapy. 2019 Mar;21(3):327-340
pubmed: 30685216
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Lab Chip. 2019 Jul 9;19(14):2456-2465
pubmed: 31210196
Sci Rep. 2020 Oct 20;10(1):17832
pubmed: 33082362
Nat Med. 2002 Jun;8(6):631-7
pubmed: 12042816
Cell Commun Signal. 2013 Jan 14;11:4
pubmed: 23317458